

## **Diagnostics review of Theranos' Technology and Final Recommendations**

Shane Weber

12/31/08

### **Overview:**

Theranos Systems (Theranos) purports to have a patient home use immunoassay in vitro diagnostic device platform. They have repeatedly introduced this platform to multiple individuals (a partial list below) at Pfizer over the last few years. The purpose of this review was to close the loop on all previous efforts for Theranos to look for business opportunities with Pfizer, and to make final recommendations regarding potential future attempts for Theranos to engage different parts of Pfizer in their platform. Theranos describes their platform as used by the patient to measure self finger pricked blood samples. The assay result is available to the patient or is provided wirelessly back to a physician. The Theranos platform is not an approved FDA diagnostic nor is a CLIA Laboratory Developed Test.

### **Recommendations:**

- 1) Theranos does not at this time have any diagnostic or clinical interest to Pfizer.
- 2) It is recommended that no further financial investment or clinical sample resources be extended to Theranos.
- 3) Going forward Theranos should be monitored by Molecular Medicine's Diagnostic group. Given Theranos' engagement of MM Oncology TAMMLs, the Diagnostics group will keep the TAMML group apprised of any relevant improvements in Theranos' technologies. A once every six month phone call (or as may be requested by Theranos upon a significant improvement to their platform) via specified point of contacts on both sides is sufficient to monitor and determine if Theranos has any demonstrated capability.

### **Review and Comments on Thernos Provided Information:**

The technical assessment review process consisted of examining Theranos confidential summary reports, reading their public patent publications, hearing their story in a one hour teleconference with questions and answers, reading their answers to a written set of technical due diligence questions submitted to them, surveying the web for public information of interest and discussing with two oncology Therapeutic Area Molecular Medicine Leads their interest for potential utility in current or for seen clinical trials.

During this process Theranos provided summary reports on studies with GlaxoSmithKline and Novartis. To date they have not responded to requests confirming that these are non-confidential reports that can be shared and so these reports have been

Pfizer Confidential

Subject to Ongoing Management Review